The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure
Open accessAbstract
Chronic human heart failure is characterized by abnormalities in β-adrenergic receptor (βAR) signaling, including increased levels of βAR kinase 1 (βARK1), which seems critical to the pathogenesis of the disease. To determine whether inhibition of βARK1 is sufficient to rescue a model of severe heart failure, we mated transgenic mice overexpressing a peptide inhibitor of βARK1 (βARKct) with transgenic mice overexpressing the sarcoplasmic reticulum Ca 2+ -binding protein, calsequestrin (CSQ). CSQ mice have a severe cardiomyopathy and markedly shortened survival (9 ± 1 weeks). In contrast, CSQ/βARKct mice exhibited a significant increase in mean survival age (15 ± 1 weeks; P < 0.0001) and showed less cardiac dilation, and cardiac function was significantly improved (CSQ vs. CSQ/βARKct, left ventricular end diastolic dimension 5.60 ± 0.17 mm vs. 4.19 ± 0.09 mm, P < 0.005; % fractional shortening, 15 ± 2 vs. 36 ± 2, P < 0.005). The enhancement of the survival rate in CSQ/βARKct mice was substantially potentiated by chronic treatment with the βAR antagonist metoprolol (CSQ/βARKct nontreated vs. CSQ/βARKct metoprolol treated, 15 ± 1 weeks vs. 25 ± 2 weeks, P < 0.0001). Thus, overexpression of the βARKct resulted in a marked prolongation in survival and improved cardiac function in a mouse model of severe cardiomyopathy that can be potentiated with β-blocker therapy. These data demonstrate a significant synergy between an established heart-failure treatment and the strategy of βARK1 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts
Bristow, M. R., Ginsburg, R., Minobe, W., Cubicciotti, R. S., Sageman, W. S., Lurie, K., Billingham, M. E., Harrison, D. C., & Stinson, E. B. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207223070401 · Cited by 2,270
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
Garg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
Self-citationHjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Ungerer, M., Böhm, M., Elce, J. S., Erdmann, E., & Lohse, M. J. (1993) · Circulation · doi:10.1161/01.cir.87.2.454 · Cited by 878
Progressive hypertrophy and heart failure in β 1 -adrenergic receptor transgenic mice
Engelhardt, S., Hein, L., Wiesmann, F., & Lohse, M. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7059 · Cited by 785
Cardiac Function in Mice Overexpressing the β-Adrenergic Receptor Kinase or a βARK Inhibitor
Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R., Bond, R. A., Milano, C. A., & Lefkowitz, R. J. (1995) · Science · doi:10.1126/science.7761854 · Cited by 719
Self-citation
Cited by
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Seven-transmembrane-spanning receptors and heart function
Rockman, H. A., Koch, W. J., & Lefkowitz, R. J. (2002) · Nature · doi:10.1038/415206a · Cited by 938
Self-citationHypertrophy of the Heart: A New Therapeutic Target?
Frey, N., Katus, H. A., Olson, E. N., & Hill, J. A. (2004) · Circulation · doi:10.1161/01.cir.0000120390.68287.bb · Cited by 851
What Is the Role of β-Adrenergic Signaling in Heart Failure?
Lohse, M. J., Engelhardt, S., & Eschenhagen, T. (2003) · Circulation Research · doi:10.1161/01.res.0000102042.83024.ca · Cited by 764
Neurohormonal activation in heart failure with reduced ejection fraction
Hartupee, J., & Mann, D. L. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.163 · Cited by 709
Metadata
- Authors
- Harding, V. B., Jones, L. R., Lefkowitz, R. J., Koch, W. J., & Rockman, H. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-05
- Volume
- 98
- Issue
- 10
- Pages
- 5809-5814
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2142377849
- Cited by
- 255
- References
- 28
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. https://app.cochat.ai/papers/10.1073/pnas.091102398
- The paper
- Harding, V. B., Jones, L. R., Lefkowitz, R. J., Koch, W. J., & Rockman, H. A. (2001). Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.091102398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.